NCT06947980View on ClinicalTrials.gov

Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 19, 2025

Primary Completion Date

July 18, 2026

Study Completion Date

November 7, 2026

Conditions
Atopic Dermatitis
Interventions
DRUG

Placebo Comparator

Placebo subcutaneous injection

BIOLOGICAL

CM512

CM512 subcutaneous injection

Trial Locations (1)

Unknown

RECRUITING

Peking University People's hospital, Beijing

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT06947980 - Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter